These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24259661)

  • 1. Dabrafenib therapy for advanced melanoma.
    Trinh VA; Davis JE; Anderson JE; Kim KB
    Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib and its potential for the treatment of metastatic melanoma.
    Menzies AM; Long GV; Murali R
    Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.
    Hecht M; Zimmer L; Loquai C; Weishaupt C; Gutzmer R; Schuster B; Gleisner S; Schulze B; Goldinger SM; Berking C; Forschner A; Clemens P; Grabenbauer G; Müller-Brenne T; Bauch J; Eich HT; Grabbe S; Schadendorf D; Schuler G; Keikavoussi P; Semrau S; Fietkau R; Distel LV; Heinzerling L
    Ann Oncol; 2015 Jun; 26(6):1238-1244. PubMed ID: 25762352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of BRAF V600 mutation in melanoma.
    Ascierto PA; Kirkwood JM; Grob JJ; Simeone E; Grimaldi AM; Maio M; Palmieri G; Testori A; Marincola FM; Mozzillo N
    J Transl Med; 2012 Jul; 10():85. PubMed ID: 22554099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
    Schilling B; Sondermann W; Zhao F; Griewank KG; Livingstone E; Sucker A; Zelba H; Weide B; Trefzer U; Wilhelm T; Loquai C; Berking C; Hassel J; Kähler KC; Utikal J; Al Ghazal P; Gutzmer R; Goldinger SM; Zimmer L; Paschen A; Hillen U; Schadendorf D;
    Ann Oncol; 2014 Mar; 25(3):747-753. PubMed ID: 24504444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From a mutation to a drug].
    Wnuk J; Wilanowski T
    Postepy Biochem; 2023 Sep; 69(3):178-187. PubMed ID: 38019740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
    Dooley AJ; Gupta A; Middleton MR
    Target Oncol; 2016 Aug; 11(4):557-63. PubMed ID: 26857260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
    Grob JJ; Amonkar MM; Martin-Algarra S; Demidov LV; Goodman V; Grotzinger K; Haney P; Kämpgen E; Karaszewska B; Mauch C; Miller WH; Millward M; Mirakhur B; Rutkowski P; Chiarion-Sileni V; Swann S; Hauschild A
    Ann Oncol; 2014 Jul; 25(7):1428-1436. PubMed ID: 24769640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma.
    Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
    Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma.
    Hagen B; Trinh VA
    J Adv Pract Oncol; 2014; 5(6):400-10. PubMed ID: 26328215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance.
    Falchook GS; Trent JC; Heinrich MC; Beadling C; Patterson J; Bastida CC; Blackman SC; Kurzrock R
    Oncotarget; 2013 Feb; 4(2):310-5. PubMed ID: 23470635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to vemurafenib can be reversible after treatment interruption: a case report of a metastatic melanoma patient.
    Mackiewicz-Wysocka M; Krokowicz Ł; Kocur J; Mackiewicz J
    Medicine (Baltimore); 2014 Dec; 93(27):e157. PubMed ID: 25501056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous effects of BRAF inhibitor therapy: a case series.
    Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
    Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research letter: BRAF-inhibitor induced panniculitis - A systematic review.
    Kye Y; Zhao G; Guhan S; Nunes D; Nguyen CV
    J Am Acad Dermatol; 2024 Feb; 90(2):420-423. PubMed ID: 37943239
    [No Abstract]   [Full Text] [Related]  

  • 17. High levels of soluble CD73 unveil resistance to BRAF inhibitors in melanoma cells.
    Giraulo C; Orlando L; Morretta E; Voli A; Plaitano P; Cicala C; Potaptschuk E; Müller CE; Tosco A; Monti MC; Morello S
    Biomed Pharmacother; 2024 Aug; 177():117033. PubMed ID: 38941889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
    Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
    J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative Analysis of the Effect of the BRAF Inhibitor Dabrafenib in 2D and 3D Cell Culture Models of Human Metastatic Melanoma Cells.
    Tovar-Parra D; Zammit-Mangion M
    In Vivo; 2024; 38(4):1579-1593. PubMed ID: 38936891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
    Ascierto PA; Simeone E; Giannarelli D; Grimaldi AM; Romano A; Mozzillo N
    J Transl Med; 2012 May; 10():107. PubMed ID: 22640478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.